<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03438981</url>
  </required_header>
  <id_info>
    <org_study_id>ML8457</org_study_id>
    <nct_id>NCT03438981</nct_id>
  </id_info>
  <brief_title>Optimization of PK/PD Target Attainment for Ceftriaxone in Critically Ill Patients With Community-acquired Pneumonia.</brief_title>
  <official_title>Impact op Capillary Leak and Hypoalbuminemia on PK/PD of Ceftriaxone in Critically Ill Patients With Overwhelming Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      WP2.1. PK/PD target attainment Plasma exposure ELF exposure WP2.2. Predictive dosing
      algorithm WP2.3. Validation WP2.4. ECMO subset
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First, We will document exposure to ceftriaxone in plasma and epithelial lining fluid.

      Second, we will try to identify risk factors for not attaining PK/PD target. Based on
      significant predictors for target non attainment we will construct a predictive dosing
      algorithm.

      In a next step this dosing algorithm will be validated in another set of ICU patients.

      Finally in a small subset of ECMO patients PK exposure will be explored.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Risk factors for target non attainment</measure>
    <time_frame>on day of sampling</time_frame>
    <description>risk factors will be assessed by comparing patients who attain target vs. those who don't</description>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Critical Illness</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma Serum Urine Broncho-alveolar lavage fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill patients receiving ceftriaxone treatment for pneumonia.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pneumonia

          -  Admitted to an ICU ward

          -  Treated with ceftriaxone

        Exclusion Criteria:

          -  Pregnancy

          -  DNR code 2-3

          -  Renal replacement therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabel Spriet, PhD PharmD</last_name>
    <role>Study Director</role>
    <affiliation>sabel.spriet@uzleuven.be</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias Gijsen, PharmD</last_name>
    <phone>+3216340087</phone>
    <email>matthias.gijsen@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabel Spriet, PhD PharmD</last_name>
    <phone>+3216341261</phone>
    <email>isabel.spriet@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZLeuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Gijsen, PharmD</last_name>
    </contact>
    <contact_backup>
      <last_name>Isabel Spriet, PharmD PhD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2018</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Matthias Gijsen</investigator_full_name>
    <investigator_title>PharmD</investigator_title>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Ceftriaxone</keyword>
  <keyword>critical illness</keyword>
  <keyword>capillary leak</keyword>
  <keyword>hypoalbuminemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Hypoalbuminemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftriaxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>To be discussed</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

